乙肝病毒携带者的转归与治疗方案和治疗方式的关系
首发时间:2008-10-02
摘要:目的选择应用多套与治疗乙肝病毒携带者有关的治疗方案,从不同的治疗角度观察不同表现类型的乙肝病毒携带者的转归与治疗方案和治疗方式选择应用的关系。方法:草分枝杆菌F.U.36 ,拉米夫定,以及中药与/或草分枝杆菌F.U.36 ,去甲斑蝥素片,以及中药等;结果:HBV-DNA阳性的乙肝病毒携带者HBV-DNA转阴率A组为93.10%,其它组别分别为79.31%,0.00%,25%,以及30%,P>0.01,HBV-DNA和HbeAg阳性的乙肝病毒携带者HBV-DNA转阴率和HbeAg血清转换率,治疗组分别为65.62%和71.87%,显著高于其它各组别的HBV-DNA的转阴率和HbeAg血清转换率分别为6.45%,3.33%,18.75%,以及21.87%和0%,0%,18.75%,以及21.87%的疗效,P>0.01。结论:AsC的疗效与AsC的结构,AsC异常免疫的存在形式,以及各种关系的解链结果有关。
关键词: HBV-DNA和HBeAg阳性的AsC HBV-DNA阳性的AsC 以抗HBV治疗为主的治疗方案 以免疫治疗为主的治疗方案。
For information in English, please click here
The outcome of asymptomatic carriers and treatment programmes and treatment of the relations
Abstract:Abstract: purpose:Application of multiple choice and treatment of asymptomatic carriers in the treatment programme, from a different point of observation of different types of performance of the vesting of asymptomatic carriers and treatment programmes and treatment of the relationship between the choice. Method: Mycobacterium Phlei F.U.36 , lamivudine,and traditional chinese medicine and / or mycobacterium phlei F.U.36, demethylcantharidin tablets , and traditional chinese medicine; results: HBV-DNA-positive asymptomatic carriers HBV-DNA A negative rate 93.10% for the group, other groups were 79.31% and 0.00%, 25% and 30%, P> 0.01, HBV-DNA and HbeAg-positive asymptomatic carriers negative rate of HBV-DNA and HbeAg serum conversion rate , The treatment group were 65.62 percent and 71.87 percent, significantly higher than that of other groups of HBV-DNA and the negative rate of HbeAg seroconversion rates were 6.45 %, 3.33 %, as well as 18.75 % and 21.87 % And 0.00 %, 0.00 %,18.75 %,as well as 21.87% of the effect, P> 0.01. Conclusion: AsC the efficacy and AsC the structure ,the abnormal immune form, as well as the results of the chain on.
Keywords: HBV-DNA and HBeAg positive AsC HBV-DNA positive AsC anti-HBV therapy treatment treatment of immune-based treatment programmes
基金:
论文图表:
引用
No.2451110276212228****
同行评议
共计0人参与
勘误表
乙肝病毒携带者的转归与治疗方案和治疗方式的关系
评论
全部评论0/1000